Belumosudil mesylate

DRUG4 trials

Sponsors

Kadmon, a Sanofi Company, M.D. Anderson Cancer Center

Conditions

Immune System Disorder (Healthy Volunteer)Multiple Myeloma

Phase 1

A Study to Determine the Effect of Multiple Oral Doses of SLx-2119 in Healthy Male Subjects

CompletedNCT05918627

Kadmon, a Sanofi CompanyImmune System Disorder (Healthy Volunteer)

Start: 2009-09-21End: 2009-12-09Updated: 2023-06-26

A Study to Determine the Effect of Multiple Oral Doses and Regimens of KD025 in Healthy Male and Post-menopausal Female Subjects

CompletedNCT05918588

Kadmon, a Sanofi CompanyImmune System Disorder (Healthy Volunteer)

Start: 2013-11-21End: 2014-03-06Updated: 2023-06-26

A Study to Determine the Effect of 500 mg Oral Dose of KD025 in Healthy Male and Post-menopausal Female Subjects

CompletedNCT05918614

Kadmon, a Sanofi CompanyImmune System Disorder (Healthy Volunteer)

Start: 2014-03-28End: 2014-06-07Updated: 2023-06-26

Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma

RecruitingNCT06105554

M.D. Anderson Cancer CenterMultiple Myeloma

Start: 2024-01-30End: 2029-08-31Target: 36Updated: 2026-08-10